From the "revamped" RVX webpage: http://resverlogix.com/programs/rvx-208-clinical-development/

"APABETALONE/RVX-208 CLINICAL DEVELOPMENT

Commencing in the fall of 2015, Resverlogix has initiated a Phase 3 clinical trial "BETonMACE" with apabetalone (also known as RVX-208) for high-risk cardiovascular disease patients with diabetes mellitus and low HDL. Approximately 15% of the patient population will also have chronic kidney disease (CKD). The primary endpoint is designed to show a relative risk reduction (RRR) of Major Adverse Cardiac Events (MACE) in this high-risk population."

Also, the table they show of past and planned clinical trials is the same one from yesterday's Annual Information Form that lists BETonMACE "Enrolling Fall 2015."

They must be pretty far along in the BETonMACE planning/approval stage to be making these bold statements in official SEDAR documents and their website now.